Slide 1: VK2735-102 Maintenance Study: Topline Results
VK2735-102 Maintenance Study: Topline Results September 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from
Slide 3: Expanding on VK2735 Holistic Weight Loss Potential
Expanding on VK2735 Holistic Weight Loss Potential VK2735 SC VK2735 SC VK2735 Oral Maintenance Phase 2 data presented 2/27/2024 Phase 2 data presented 8/19/2025 Maintenance data presented today • Up to 14.7% body weight reduction • Up to 12.2% body weight reduction • Potential to unlock new platform
Slide 4: VK2735-102: Maintenance Study Design
VK2735-102: Maintenance Study Design Part 1: Subcutaneous (SC) maintenance dosing • Designed to evaluate transition from Weekly (QW) to SC monthly (QM) or every other week (QOW) dosing regimens • Endpoints: Safety, tolerability, PK, weight change 1.25 2.5 mg mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg
Slide 5: Maintenance Study: Induction Weight Loss Through Week 21
Maintenance Study: Induction Weight Loss Through Week 21 Body Weight Percent Change from Baseline over 13 Weeks (LSM±SE) • Significant and progressive reduction in body weight observed after 21 weeks in all VK2735 cohorts • Up to approximately 19% weight loss from baseline • 17.8% weight loss from b
Slide 6: High Proportion of VK2735 Participants Achieve Key Weight Loss Thresholds at Week 21
High Proportion of VK2735 Participants Achieve Key Weight Loss Thresholds at Week 21 5% Weight Loss 10% Weight Loss 15% Weight Loss 20% Weight Loss VK2735, Combined 1 98% 90% 65% 32% n=143 Placebo 13% 0% 0% 0% n=15 p-value vs. placebo <0.0001 <0.0001 <0.0001 <0.01 Notes: 1) Observed values for subje
Slide 7: Maintenance Study: Maintenance of Weight Loss with Every-Other-Week Dosing
Maintenance Study: Maintenance of Weight Loss with Every- Other-Week Dosing Percent of Weight Loss Maintained from W21 to W33 (LSM±SE) • Up to approximately 97% maintenance of weight loss observed following transition to every-other-week dosing • Compares favorably to 61% maintenance effect for part
Slide 8: Maintenance Study: Maintenance of Weight Loss with Monthly Dosing
Maintenance Study: Maintenance of Weight Loss with Monthly Dosing Percent of Weight Loss Maintained from W21 to W33 (LSM±SE) • Up to approximately 90% maintenance of weight loss observed following transition to monthly dosing • Compares favorably to 61% maintenance effect for participants transition
Slide 9: Maintenance Study: 17.5 mg Weekly Dosing Provides Highly Competitive 22% Weight Loss at W33
Maintenance Study: 17.5 mg Weekly Dosing Provides Highly Competitive 22% Weight Loss at W33 Body Weight Percent Change from Baseline over 33 Weeks (LSM±SE) • Continued weekly dosing at 17.5 mg leads to progressive weight loss of up to approximately 22% • No plateau observed, suggesting continued wei
Slide 10: Discontinuation and GI Tolerability Summary – Induction Phase Through Week 21
Discontinuation and GI Tolerability Summary – Induction Phase Through Week 21 Dose Level1,2 Placebo VK2735 VK2735 VK2735 VK2735 VK2735 (n=15) Combined 15 mg QW 17.5 mg QW 20 mg QW 22.5 mg QW (n=166) (n=15) (n=121) (n=15) (n=15) Discontinued treatment early 0 (0%) 22 (13%) 2 (13%) 15 (12%) 1 (7%) 4 (
Slide 11: Discontinuation and GI Tolerability Summary – Every Other Week Maintenance Dosing Through Week 33
Discontinuation and GI Tolerability Summary – Every Other Week Maintenance Dosing Through Week 33 Dose Level1,2 Placebo VK2735 VK2735 VK2735 VK2735 (n=27) Combined QOW 5.0 mg QOW 7.5 mg QOW 10.0 mg QOW (n=37) (n=12) (n=13) (n=12) Discontinued treatment early 0 (0%) 1 (3%) 0 (0%) 0 (0%) 1 (8%) Discon
Slide 12: Discontinuation and GI Tolerability Summary – Monthly Maintenance Dosing Through Week 33
Discontinuation and GI Tolerability Summary – Monthly Maintenance Dosing Through Week 33 Dose Level1,2 Placebo VK2735 VK2735 VK2735 VK2735 VK2735 VK2735 (n=27) Combined QM 10 mg QM 15 mg QM 17.5 mg QM 20 mg QM 22.5 mg QM (n=66) (n=16) (n=14) (n=11) (n=14) (n=11) Discontinued treatment early 0 (0%) 3
Slide 13: VK2735-102 Study Establishes Maintenance Use Case
VK2735-102 Study Establishes Maintenance Use Case • Rapid Induction with Durable, Tolerable Maintenance Potential Rapid Weight Sustained Loss on Tolerability Potentially Loss Induction Maintenance Dosing Amenable for Long Term Use • Up to ~19% placebo-adj weight loss • Up to ~90% (monthly dosing) an
Slide 14: VK2735-102 Maintenance Study: Topline Results
VK2735-102 Maintenance Study: Topline Results September 2026